Showing results (2441-2450 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 14, 2011
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donorsMartin Schmidt-Hieber, Robert Dabrowski, Babette Aicher, et al.
Investigational New Drugs|July 27, 2011
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosisAhmad Raza, Blake A Jacobson, Adam Benoit, et al.
Investigational New Drugs|December 8, 2010
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinibNathalie Lassau, Linda Chami, Serge Koscielny, et al.
Investigational New Drugs|November 17, 2010
A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeletonJin Zhang, Jing Zhou, Xiaomei Ren, et al.
Investigational New Drugs|April 13, 2011
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trialsAxel Le Cesne, Alejandro Yovine, Jean-Yves Blay, et al.
Investigational New Drugs|May 20, 2011
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapyGyörgy Bodoky, Constanta Timcheva, David Robert Spigel, et al.
Investigational New Drugs|February 1, 1990
Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group studyN A Iscoe, E A Eisenhauer, A J Bodurtha
Investigational New Drugs|August 10, 2011
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumorsJ Paul Monk, Miguel Villalona-Calero, Joe Larkin, et al.
Investigational New Drugs|June 30, 2011
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cellsAnsgar Brüning, Petra Burger, Andrea Gingelmaier, et al.
Investigational New Drugs|December 14, 2011
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancerNatsuko T Okita, Taito Esaki, Eishi Baba, et al.
Pageof 372